AstraZeneca Amends China Collaboration Agreement With Ironwood
September 18 2019 - 2:46AM
Dow Jones News
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Wednesday that it will assume sole
responsibility for developing, manufacturing and commercializing
Ironwood Pharmaceuticals Inc.'s (IRWD) Linzess drug in China after
amending a collaboration agreement.
The FTSE 100-listed company said Cambridge, Mass.-based biotech
company Ironwood will no longer be involved in the research and
development or the commercialization of Linzess, a treatment for
patients with irritable bowel syndrome with constipation, and that
manufacturing responsibility will also be transferred to
AstraZeneca.
The two companies entered into a collaboration pact in 2012,
AstraZeneca said. Under the original agreement, both companies were
jointly responsible for strategic oversight of the development and
commercialization of Linzess in China, while AstraZeneca had
primary responsibility for local operational execution.
Linzess was approved by China's National Medical Products
Administration for adults with irritable bowel syndrome with
constipation in January and is expected to be launched later this
year, AstraZeneca said.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
September 18, 2019 02:31 ET (06:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024